# INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE

> **NCT03871517** · PHASE4 · COMPLETED · sponsor: **Beijing Tiantan Hospital** · enrollment: 5438 (actual)

## Conditions studied

- Ischemic Stroke
- Indobufen
- Aspirin

## Interventions

- **DRUG:** Indobufen
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT03871517
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-03
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 5438 (ACTUAL)
- **Last updated:** 2023-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03871517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03871517, "INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03871517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*